clobetasol and Cicatrix

Lichen planopilaris (LPP) is one of the important causes of cicatricial alopecia. We aimed to evaluate the efficacy and safety of low-dose naltrexone (LDN) in the setting of a clinical trial in patients with LPP.. We included patients with LPP between 2018 and 2020. Patients were allocated to two groups. The first group received topical clobetasol plus oral low dose naltrexone (3 mg) while the second received topical clobetasol plus placebo. The assessment was made for the disease severity by lichen planopilaris activity index (LPPAI) instrument and the safety of the drug in 2-month intervals up to 6 months. To compare both groups, we used the ANOVA test for repeated measures. Clinical trials registry code: IRCT20180809040747N1.. Thirty-four patients were analyzed in an intention-to-treat fashion. There was a decrescendo pattern on LPPAI scores that was statistically significant within the LDN (. Low-dose naltrexone (3 mg) failed to improve the severity of the LPP more than what is achievable with topical clobetasol.

Topics: Alopecia; Cicatrix; Clobetasol; Humans; Lichen Planus; Naltrexone

Postinflammatory hyperpigmentation (PIH) is the most common adverse effect of laser treatment in dark-skinned individuals. Little is known whether PIH can be prevented or minimised. The objective of this study was to investigate the effect of short-term application of topical corticosteroids on the incidence of PIH after ablative fractional resurfacing in Asians. Forty subjects with skin phototype IV and atrophic acne scars were treated with a fractional CO2 laser on both sides of the face. Post-operatively, clobetasol propionate 0.05% ointment was applied to one randomly selected side of the face for the first 2 days, followed by an application of petrolatum jelly for the rest of the week (petrolatum was applied to the other side for 7 days). Assessments on the clinical outcome, the wound healing process and the occurrence of PIH were obtained once weekly for the first month and at 2 and 3 months post-treatment. The side of the face treated with petrolatum alone had significantly (p < 0.001) higher incidence of PIH (75%) after laser irradiation than the side of the face treated with topical corticosteroids and petrolatum (40%). The PIH occurring on the petrolatum-treated sides had significantly higher intensity (p < 0.001) and was spread over a significantly larger area (p < 0.001), compared with the corticosteroid- and petrolatum-treated sides. In conclusion, a short-term application of topical corticosteroids postoperatively is associated with a decreased risk of PIH after ablative fractional resurfacing.

Topics: Acne Vulgaris; Administration, Cutaneous; Adrenal Cortex Hormones; Asian People; Cicatrix; Clobetasol; Dermatitis; Dermatologic Surgical Procedures; Female; Humans; Hyperpigmentation; Laser Therapy; Lasers, Gas; Male; Single-Blind Method; Skin Pigmentation; Thailand; Time Factors; Treatment Outcome

Topics: Aged, 80 and over; Cicatrix; Clobetasol; Glucocorticoids; Humans; Leg Injuries; Male; Pemphigoid, Bullous; Recurrence; Time Factors

BACKGROUND Classical pyoderma gangrenosum is a rare, inflammatory, neutrophilic dermatosis that commonly presents with severe ulcerations on the lower extremities and is often misdiagnosed and mistreated. Delay in treatments can lead to worsening of the ulcerations and allows for multiple comorbid factors. Pyoderma gangrenosum is most commonly treated with immunosuppressants or anti-inflammatory agents and is often worsened by surgical procedures due to the presence of pathergy. In acute cases, a course of anti-inflammatory treatments works well in alleviating symptoms and reducing ulcerations and residual scarring. However, in chronic cases with the presence of severe scarring and necrotic ulcerations, the simple implementation of systemic immunosuppressants is frequently ineffective alone. Although not mentioned in most case reports on pyoderma gangrenosum, the chronicity of its inflammatory component can lead to necrosis and scarring and subsequent vascular insufficiency. CASE REPORT We present a severe case of chronic ulcerative pyoderma gangrenosum in a patient who had treatment-resistant ulcerations and cribriform edematous scarring with subsequent vascular insufficiency of the right lower extremity. This patient, while receiving topical clobetasol, had marked improvement in the healing of his ulcerations only after starting a novel course of cadexomer iodine, compression stockings, and pentoxifylline. CONCLUSIONS The efficacy of non-anti-inflammatory treatments indicates that chronic pyoderma gangrenosum with extensive scarring is commonly associated with the comorbid factors of vascular insufficiency, necrotic debris, and extensive wound fluid. In cases of ulcerations in chronic pyoderma gangrenosum that are resistant to anti-inflammatory treatments alone, one should identify and address other compounding factors that may inhibit wound healing.

Topics: Adult; Anti-Infective Agents, Local; Anti-Inflammatory Agents; Chronic Disease; Cicatrix; Clobetasol; Combined Modality Therapy; Comorbidity; Humans; Iodophors; Leg; Leg Ulcer; Male; Pentoxifylline; Peripheral Vascular Diseases; Pyoderma Gangrenosum; Stockings, Compression; Vasodilator Agents

Primary cicatricial alopecia (PCA) is a dermatological challenge. Because no large-scale epidemiological study regarding PCA is available yet, we investigated the National Health Insurance Service-National Sample Cohort for patients diagnosed with PCA. The annual and overall rates of incidence and prevalence of PCA during the study period (2004-2013) were estimated. Distribution of PCA subtypes, disease co-occurrence rates and frequently prescribed medications were also evaluated. The overall incidence was 6.10 (95% confidence interval [CI], 5.62-6.60) per 100 000 person-years. The incidence rate was stable over time (risk ratio [RR] = 1.012, P = 0.201) and lower in female patients (RR = 0.718, P < 0.001). The overall prevalence was 20.93 (95% CI, 17.97-23.86) per 100 000 persons. The average duration of PCA was calculated as 3.23 years. Approximately 70% of the patients were below the age of 45 years. Folliculitis decalvans and dissecting cellulitis were the most common subtypes of PCA. Logistic regression analysis showed that PCA was significantly associated with thyroid disorders (adjusted odds ratio = 1.64, P < 0.001). Clobetasol was the most frequently prescribed topical agent. Corticosteroids were the most common oral agents used, followed by tetracycline antibiotics. Our study is the first large-scale study reporting the epidemiology of PCA. We found a preponderance of males and neutrophil-associated subtypes of PCA, and PCA was related to thyroid disorders.

Topics: Administration, Oral; Administration, Topical; Adolescent; Adult; Age Distribution; Alopecia; Anti-Bacterial Agents; Asian People; Cellulitis; Child; Child, Preschool; Cicatrix; Clobetasol; Female; Folliculitis; Glucocorticoids; Humans; Incidence; Infant; Infant, Newborn; Male; Middle Aged; Prevalence; Republic of Korea; Retrospective Studies; Risk Factors; Sex Distribution; Skin; Young Adult

Frontal fibrosing alopecia (FFA) is a lichen planopilaris-variant scarring alopecia that has rarely been described in men.. To characterize the clinicopathologic findings of FFA in men by studying a series of 7 male patients.. We conducted a retrospective review of all cases of male patients with FFA at the Mayo Clinic from 1992 to 2016.. Seven male patients with FFA were identified. The frontal scalp (in 6 of 7 patients), sideburns (in 4 of 7), and temporal scalp (in 4 of 7) were most frequently involved. Three patients had involvement of the eyebrows. One patient had hair loss of the upper cutaneous lip. All patients had biopsy evidence of lichen planopilaris. None of the patients had associated autoimmune or thyroid disease. Two patients had hypogonadism upon testosterone studies.. Limitations include small sample size and varied follow-up.. Although most often reported among postmenopausal women, FFA also occurs among men. The clinical and histopathologic characteristics of FFA in men parallel those described in women with FFA. Unique areas of involvement in men include sideburns and facial hair. Concomitant mucocutaneous lichen planus, autoimmune disease, and thyroid disease are infrequent among men with FFA. Distribution of hair loss and associated hormonal abnormalities aid in the recognition of FFA in men.

Topics: Adult; Aged; Alopecia; Anti-Inflammatory Agents; Cheek; Cicatrix; Clobetasol; Dermatologic Agents; Eyebrows; Forehead; Humans; Hydroxychloroquine; Lichen Planus; Male; Middle Aged; Retrospective Studies; Scalp; Tacrolimus

Deep erythema and inflammation after re-epithelialization of superficial wounds is a sign of scar formation. Corticosteroids may prevent scarring by suppression of inflammation and fibroblast activity. Tretinoin may increase the efficacy of corticosteroids in this setting.. To evaluate the efficacy of corticosteroids plus tretinoin for prevention of scars after superficial wounds.. In a retrospective study of patients with superficial partial thickness thermal skin burn, we compared the patients who received clobetasol plus tretinoin after re-epithelialization with patients who did not receive any medication. Clobetasol propionate 0.05% ointment was used twice daily with overnight occlusive dressing in conjunction with twice weekly topical tretinoin 0.05% cream.. Among 43 patients who had light pink or no erythema after re-epithelialization and consequently did not receive clobetasol + tretinoin, no scar was developed. Among patients who had deep erythema after re-epithelialization, rate of scar formation was significantly higher in 14 patients who did not receive clobetasol + tretinoin than in 21 patients who received clobetasol + tretinoin (64% and 19%, respectively; p = 0.01).. Clobetasol + tretinoin can significantly decrease the incidence of scar formation in patients with inflammation after re-epithelialization of superficial wounds.

Topics: Adolescent; Adult; Aged; Burns; Child; Child, Preschool; Cicatrix; Clobetasol; Dermatologic Agents; Erythema; Female; Glucocorticoids; Humans; Male; Middle Aged; Occlusive Dressings; Re-Epithelialization; Retrospective Studies; Skin; Tretinoin; Ulcer; Young Adult

We describe details of a very rare variant of lichen sclerosus in an elderly man. This pattern was characterized by involvement of most of the body surface by bullae, erosions and scarring, including scarring alopecia. Our patient responded to topical corticosteroids and doxycycline. Borrelia spp. have been implicated in a previous case of this variant, but we could not find any evidence of this in our patient.

Topics: Aged, 80 and over; Alopecia; Cicatrix; Clobetasol; Glucocorticoids; Humans; Lichen Sclerosus et Atrophicus; Male; Skin

The bone-anchored hearing aid (BAHA) osseointegrated cochlear stimulator can treat hearing loss in a variety of clinical situations. Occasionally skin/scar overgrowth may cover the abutment. This overgrowth interferes with affixing the BAHA to the abutment. Surgical scar revision/excision has been used to treat this problem. Clobetasol (0.05%), a steroid gel, can reduce skin overgrowth. Experience with skin overgrowth and the efficacy of clobetasol to treat this problem was reviewed.. The authors conducted a retrospective analysis of patients who underwent BAHA abutment implantation from January 2003 through December 2006.. Eighty-eight patients (2 patients received bilateral BAHAs) were reviewed. Twenty (22%) of 90 sites developed overgrowth. Thirteen of 20 sites were treated with clobetasol. The overgrowth resolved in 11 (85%) of 13 sites after treatment. Patients with incomplete skin graft survival were significantly more likely to develop skin overgrowth (P = 0.0017).. Clobetasol is an effective treatment for abutment skin/scar overgrowth. Clobetasol allows patients to resume BAHA use and obviates the need for scar revision.

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Cicatrix; Clobetasol; Female; Gels; Glucocorticoids; Hearing Aids; Hearing Loss; Humans; Male; Mastoid; Middle Aged; Retrospective Studies; Treatment Outcome

To determine whether the abundance of newly formed collagen in healing surgical wounds correlated with scar severity, and whether topical application of steroid cream reduced new collagen formation in patients who have undergone median sternotomy.. Thirty three patients six weeks after sternotomy, and 12 controls were studied. Scars were photographed, and biopsy specimens from scars at sites treated or untreated with topical corticosteroids (clobetasol proprionate 0.5%) were examined using immunohistochemical staining for type 1 procollagen (PCP 1) and transforming growth factor beta (TGF-beta), and in situ hybridisation for type 1 procollagen messenger RNA (mRNA).. The degree of hypertrophy of the scar and the abundance of PCP 1 immunostaining were ranked independently, blind, and a correlation between these two variables was observed (r = 0.604, p < 0.001). The PCP 1 immunostaining was accompanied by a great abundance of PCP 1 mRNA and only a slight increase in TGF-beta immunostaining, when compared with normal skin or mature scars. Following the application of topical corticosteroids, for either 48 hours or twice daily for seven days, there was no reduction in PCP 1 immunostaining nor the abundance of PCP 1 mRNA.. These data suggest that the extent of new collagen formation as assessed by PCP 1 immunohistochemistry may be a useful marker of the exuberance of the scarring process following sternotomy, and that topical corticosteroids are ineffective in reducing this component of the fibrotic response.

Topics: Base Sequence; Biomarkers; Cicatrix; Clobetasol; Humans; Immunohistochemistry; In Situ Hybridization; Molecular Sequence Data; Procollagen; RNA, Messenger; Skin; Sternum; Transforming Growth Factor beta